MGF

Overview

Mechano Growth Factor (MGF), also known as IGF-1Ec in humans, is a splice variant of the insulin-like growth factor 1 (IGF-1) gene that is expressed locally in skeletal muscle and other tissues in response to mechanical loading, exercise, or tissue damage. Unlike systemic IGF-1 produced primarily by the liver under growth hormone (GH) stimulation, MGF acts in an autocrine/paracrine fashion at the site of tissue stress. Its unique E-domain (the C-terminal peptide extension that distinguishes it from the IGF-1Ea isoform) is responsible for activating quiescent muscle satellite cells — the resident stem cell population required for muscle fiber repair, regeneration, and hypertrophy — making MGF a critical initiator of the muscle repair cascade that precedes the sustained anabolic signaling of mature IGF-1.

The physiological role of MGF has been elucidated through studies showing rapid but transient upregulation following eccentric exercise, resistance training, and muscle injury. This initial MGF pulse activates satellite cells, promoting their proliferation and delaying differentiation, thereby expanding the myogenic precursor pool available for subsequent fusion into damaged or growing muscle fibers. Once the MGF signal subsides, IGF-1Ea takes over to drive differentiation and protein synthesis. Synthetic MGF peptide (typically the 24-amino-acid E-domain fragment) has been investigated for its ability to replicate this satellite cell activation when administered exogenously. Research in animal models has demonstrated that local MGF injection can enhance muscle regeneration after injury, reduce scar tissue formation, and protect cardiac tissue following ischemia. Neurological studies have also shown MGF's neuroprotective effects in models of neurodegenerative disease and brain ischemia.

The synthetic peptide PEG-MGF (polyethylene glycol-conjugated MGF) was developed to extend the extremely short half-life of native MGF (which is degraded within minutes in circulation) to several hours, enabling systemic administration. PEG-MGF is commonly discussed in research and performance contexts alongside IGF-1 LR3 and IGF-1 DES, though each variant has distinct receptor binding kinetics and tissue specificity. MGF is particularly valued for localized injection protocols targeting specific muscle groups or injury sites. It is often incorporated into recovery-focused stacks with growth hormone secretagogues such as CJC-1295 and Ipamorelin. As a research peptide, MGF is not approved for human clinical use, and quality sourcing remains a significant concern.

Mechanism of Action

MGF (Mechano-Growth Factor) is a splice variant of the IGF-1 gene (specifically the IGF-1Ec isoform in humans) that is produced in response to mechanical stress and tissue damage. Unlike systemic IGF-1, MGF acts in an autocrine/paracrine fashion at the site of tissue injury. Its primary mechanism involves activation of satellite cells (muscle stem cells) through the extracellular signal-regulated kinase (ERK) pathway. MGF binds to a distinct receptor (not the canonical IGF-1R) and triggers ERK1/2 phosphorylation, which promotes satellite cell proliferation without premature differentiation, thereby expanding the pool of myogenic precursor cells available for muscle repair.

Downstream of ERK activation, MGF upregulates several key transcription factors including MyoD and myogenin that govern myoblast commitment and fusion into mature myofibers. MGF also activates the PI3K/Akt/mTOR signaling cascade, promoting protein synthesis and inhibiting proteolytic pathways such as the ubiquitin-proteasome system and muscle-specific E3 ligases (MuRF1, MAFbx/atrogin-1). Additionally, MGF has been shown to exert neuroprotective effects by reducing oxidative stress and apoptosis in neuronal cells through Akt-mediated phosphorylation of Bad and caspase-9 suppression.

Therapeutically, MGF's unique capacity to activate satellite cells makes it a candidate for treating sarcopenia, muscular dystrophies, and age-related muscle wasting. Its neuroprotective properties suggest potential applications in neurodegenerative diseases and ischemic brain injury. MGF also promotes cardiac repair following myocardial infarction by mobilizing cardiac progenitor cells and reducing fibrosis through TGF-beta pathway modulation.

Reconstitution Calculator

Safety Profile

As an activator of the IGF-1 pathway, MGF carries a theoretical risk of promoting pre-existing malignancies. Contraindications include a history of cancer, and it should not be used during pregnancy or by those with uncontrolled diabetes. Long-term human safety data is limited, and most evidence comes from animal studies.

Pharmacokinetic Profile